Pretreatment homocysteine and molecular endothelial risk in transgender women starting estrogen-based hormone therapy

2025/09/10 by Daniele Tienforti, Giovanni Terrana, Adriano Ciriani +3
Psychology · Medicine · #LGBTQ Health, Identity, and Policy #Folate and B Vitamins Research #Pregnancy and Medication Impact

paper · doi:10.1080/26895269.2025.2556972

Abstract

Cardiovascular risk prediction tools such as SCORE2 and the Framingham Risk Score were developed for middle-aged and older adults (typically ≥40 years) and often substantially underestimate vascula...

Citations

• Standards of Care for the Health of Transgender and Gender Diverse People, Version 8

Related

• Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy
• Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons
• Differential cardiovascular risks of menopausal hormone therapy: insights from a Korean cohort
• Sex steroid hormones and subclinical atherosclerosis progression in postmenopausal women
• Gender-affirming hormone therapy and its impact on myocardial mass and cardiac function: a prospective magnetic resonance cohort study on transgender men and women